KRAS and colorectal cancer: Median PFS/OS was 1.4/7.1 months in the BRAF-mutant colorectal cancer cohort, 1.5/4.7 months in the KRAS-mutant colorectal cancer 45 mg dose cohort, 3.5/9.1 months in the KRAS-mutant colorectal cancer 60 mg dose cohort, and 2.1/4.8 months in the biliary cohort.